1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021

Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021

  • July 2021
  • 60 pages
  • ID: 5974301
  • Format: PDF
  • Delve Insight


Table of Contents

“Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Non-Cystic Fibrosis Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Non-Cystic Fibrosis Bronchiectasis Understanding

Non-Cystic Fibrosis Bronchiectasis: Overview
Non–cystic fibrosis (non-CF) bronchiectasis is a progressive respiratory disease characterized by a permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes. The symptoms and clinical course of NCFB are variable. Some patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily. The classic clinical manifestations of this clinical condition are cough and daily mucopurulent sputum production, often lasting months to years. Blood-streaked sputum or hemoptysis may result from airway damage associated with acute infection. Dyspnea and wheezing occur in 75% of patients. Pleuritic chest pain occurs in 50% of patients and reflects the presence of distended peripheral airways or distal pneumonitis adjacent to a visceral pleural surface. Physical examination of the chest shows adventitious breath sounds, such as crackles (70%), wheezing (34%) or rhonchi (44%).

"Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis pipeline landscape is provided which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis treatment guidelines. The assessment part of the report embraces, in depth Non-Cystic Fibrosis Bronchiectasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Non-Cystic Fibrosis Bronchiectasis R&D. The therapies under development are focused on novel approaches to treat/improve Non-Cystic Fibrosis Bronchiectasis.

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Chapters
This segment of the Non-Cystic Fibrosis Bronchiectasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs
• Brensocatib: Insmed Incorporated
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Cystic Fibrosis Bronchiectasis.

• CSL787: CSL Behring
It is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease.
Further product details are provided in the report……..

Non-Cystic Fibrosis Bronchiectasis: Therapeutic Assessment
This segment of the report provides insights about the different Non-Cystic Fibrosis Bronchiectasis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Non-Cystic Fibrosis Bronchiectasis
There are approx. 5+ key companies which are developing the therapies for Non-Cystic Fibrosis Bronchiectasis. The companies which have their Non-Cystic Fibrosis Bronchiectasis drug candidates in the most advanced stage, i.e. phase III include, Insmed Incorporated.

• Phases
This report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Inhalation
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non-Cystic Fibrosis Bronchiectasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Cystic Fibrosis Bronchiectasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Cystic Fibrosis Bronchiectasis drugs.

Non-Cystic Fibrosis Bronchiectasis Report Insights
• Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Non-Cystic Fibrosis Bronchiectasis Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Non-Cystic Fibrosis Bronchiectasis drugs?
• How many Non-Cystic Fibrosis Bronchiectasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Cystic Fibrosis Bronchiectasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Cystic Fibrosis Bronchiectasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non-Cystic Fibrosis Bronchiectasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Insmed Incorporated
• CSL Behring
• Boehringer Ingelheim
• Novartis

Key Products
• Brensocatib
• CSL787
• BI 1323495
• Tobramycin inhalation powder
• Lonodelestat

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on